Key result
Rivaroxaban plus aspirin fatal bleeding is linked to concurrent risk factors in ~95% of cases.
Why the study?
The study aimed to analyze the clinical characteristics of fatal adverse events associated with the combined use of rivaroxaban and aspirin and to emphasize rational drug use.
Population
2309 fatal adverse event reports of rivaroxaban combined with aspirin from 21 countries in VigiBase
Design
Pharmacovigilance database analysis
Authors
Loading...
Alerts to fatal bleeding risks with rivaroxaban-aspirin in elderly patients with risk factors or errors; leaves open net benefit in stable vascular disease.
Observational (n=2,309)
Fatal adverse events from the combination of rivaroxaban and aspirin are predominantly severe bleeding events occurring in elderly patients with multiple concurrent risk factors or medication errors.
Zhang et al. (2022) conducted an observational in Fatal adverse events in patients taking rivaroxaban and aspirin (n=2,309). Rivaroxaban combined with aspirin was evaluated on Characteristics of fatal adverse events. Fatal adverse events related to rivaroxaban combined with aspirin mainly manifested as serious bleeding, with 95% of bleeding cases having concurrent risk factors and 20% involving medication errors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: